Azeria Therapeutics has wound down voluntarily four years after being set up to advance University of Cambridge and Cancer Research UK work.

Azeria Therapeutics, a UK-based oncology spinout of University of Cambridge and research charity Cancer Research UK (CRUK), has wound down voluntarily and returned “a substantial amount of funds” to investors, according to BusinessWeekly. The spinout formally made the decision to halt operations in December 2020, according to a regulatory filing, and had appointed Stephen Adshead…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.